Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Synthesis  




2 See also  




3 References  













Caroxazone






●العربية
 ●فارسی
 ●Português
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Türkçe
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Caroxazone
Clinical data
Pregnancy
category
  • ?
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
    • Identifiers

    • 2-(2-oxo-4H-1,3-benzoxazin-3-yl)acetamide

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.038.481 Edit this at Wikidata
    Chemical and physical data
    FormulaC10H10N2O3
    Molar mass206.201 g·mol−1
    3D model (JSmol)

    • O=C(N)CN2C(=O)Oc1ccccc1C2

    Caroxazone (Surodil, Timostenil) is an antidepressant which was formerly used for the treatment of depression but is now no longer marketed.[2][3] It acts as a reversible monoamine oxidase inhibitor (RIMA) of both MAO-A and MAO-B subtypes, with five-fold preference for the latter.[4][5][6][7][8]

    Synthesis[edit]

    Caroxazone synthesis:[9][10][11][12][13]

    Synthesis starts by reductive aminationofsalicylaldehyde and glycinamide to give 3. The synthesis is completed by reaction with phosgene and NaHCO3.

    See also[edit]

    References[edit]

    1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  • ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
  • ^ Cecchini S, Petri P, Ardito R, Bareggi SR, Torriti A (1978). "A comparative double-blind trial of the new antidepressant caroxazone and amitriptyline". The Journal of International Medical Research. 6 (5): 388–94. doi:10.1177/030006057800600507. PMID 359383. S2CID 40464443.
  • ^ Monoamine oxidase inhibitors in neurological diseases. New York: M. Dekker. 1994. ISBN 0-8247-9082-0.
  • ^ Moretti A, Caccia C, Martini A, Bonollo L, Amico A, Sega R, et al. (May 1981). "Effect of caroxazone, a new antidepressant drug, on monoamine oxidases in healthy volunteers". British Journal of Clinical Pharmacology. 11 (5): 511–5. doi:10.1111/j.1365-2125.1981.tb01158.x. PMC 1401585. PMID 7272163.
  • ^ Moretti A, Caccia C, Calderini G, Menozzi M, Amico A (October 1981). "Studies on the mechanism of action of caroxazone, a new antidepressant drug". Biochemical Pharmacology. 30 (19): 2728–31. doi:10.1016/0006-2952(81)90549-9. PMID 6170295.
  • ^ Martini A, Bonollo L, Nicolis FB, Sega R, Palermo A (June 1981). "Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to oral tyramine in man". British Journal of Clinical Pharmacology. 11 (6): 611–5. doi:10.1111/j.1365-2125.1981.tb01178.x. PMC 1402186. PMID 7272178.
  • ^ Martini A, Bonollo L, Nicolis FB, Sega R, Palermo A, Braibanti E (June 1981). "Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to intravenous tyramine in man". British Journal of Clinical Pharmacology. 11 (6): 605–10. doi:10.1111/j.1365-2125.1981.tb01177.x. PMC 1402193. PMID 7272177.
  • ^ Bernardi L, Coda S, Nicolella V, Vicario GP, Gioia B, Minghetti A, et al. (1979). "Radioisotopic and synthetic studies related to caroxazone metabolism in man". Arzneimittel-Forschung. 29 (9): 1412–6. PMID 583252.
  • ^ Bernardi L, Coda S, Pegrassi L, Suchowsky GK (August 1968). "Pharmacological properties of some derivatives of 1,3-benzoxazine". Experientia. 24 (8): 774–5. doi:10.1007/bf02144859. PMID 5683159. S2CID 30917127.
  • ^ Bernardi L, Coda S, Bonsignori A, Pegrassi L, Suchowsky GK (August 1969). "Central depressant properties of 3,1-benzoxazine derivates". Experientia. 25 (8): 787–8. doi:10.1007/bf01897874. PMID 5348526. S2CID 5347811.
  • ^ GB 1115759, "Carboxamidoalkyl-1,3-benzoxazines", published 1968-05-29, assigned to Societa Farmaceutici Italia 
  • ^ L. Bernardi et al., U.S. patent 3,427,313 (1969 to Soc. Farma. Italia).

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Caroxazone&oldid=1170631334"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Benzoxazines
     ●Carbamates
     Hidden categories: 
    ●CS1 Brazilian Portuguese-language sources (pt-br)
     ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●ECHA InfoCard ID from Wikidata
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 16 August 2023, at 06:54 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki